Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension

MC. Genovese, J. Glover, M. Greenwald, W. Porawska, EC. El Khouri, E. Dokoupilova, JI. Vargas, M. Stanislavchuk, H. Kellner, E. Baranova, N. Matsunaga, R. Alten,

. 2019 ; 21 (1) : 281. [pub] 20191212

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028710

OBJECTIVE: To compare the efficacy, serum drug concentrations, immunogenicity, and safety of FKB327 with the adalimumab reference product (RP) in combination with methotrexate in patients with moderate-to-severe, active rheumatoid arthritis (RA). METHODS: Patients were randomized 1:1 in a double-blind study (NCT02260791), received 40 mg of FKB327 or RP by subcutaneous injection every other week for 24 weeks (Period I), then re-randomized 2:1, remaining on the same study drug or switching to the other up to week 54 in an open-label extension (Period II, NCT02405780). Efficacy was evaluated using American College of Rheumatology (ACR20) response rate difference at week 24 with equivalence margins of ± 13% and - 12% to + 15% using 95% and 90% confidence intervals (CIs), respectively. Efficacy, serum drug concentrations, immunogenicity, and safety were compared at week 54. RESULTS: A total of 730 patients were randomized in Period I (n = 367 FKB327, n = 363 RP), and 645 transitioned to Period II (n = 216 FKB327-FKB327, n = 108 FKB327-RP, n = 108 RP-FKB327, n = 213 RP-RP). At week 24, ACR20 response rates were 74.1% with FKB327 versus 75.7% with RP. 95% and 90% CI of the response rate difference were - 7.9 to 4.7% and - 7.3 to 3.6%, respectively, meeting predefined equivalence margins. The ACR20 response rate remained over 70% of patients to week 54 with all treatment sequences. In Period I, mean trough serum drug concentrations were slightly higher for patients receiving FKB327 than those receiving RP. Mean concentrations were stable over time and reflected steady state in Period II. The proportions of patients with samples positive for neutralizing antidrug antibodies (ADAs) were comparable (57.7% with FKB327 vs. 55.5% with RP) at week 24, and no consistent difference in ADA were seen between continuous and switched treatments in Period II. Efficacy was slightly reduced in the small proportion of patients with high ADA titers in all treatment groups. No clinically significant differences were observed in the incidence of commonly reported treatment-emergent adverse events between the treatments across Periods I and II. CONCLUSION: FKB327 was equivalent to RP in clinical efficacy and demonstrated comparable safety and immunogenicity in patients with moderate-to-severe RA. No effect of switching between FKB327 and RP was observed. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02260791, Registered 29 July 2014. ClinicalTrials.gov, NCT02405780, Registered 17 July 2015.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028710
003      
CZ-PrNML
005      
20210114154819.0
007      
ta
008      
210105s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13075-019-2046-0 $2 doi
035    __
$a (PubMed)31831079
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Genovese, Mark C $u Division of Immunology and Rheumatology, Stanford University, 1000 Welch Rd, #203, Palo Alto, CA, USA. genovese@stanford.edu.
245    10
$a FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension / $c MC. Genovese, J. Glover, M. Greenwald, W. Porawska, EC. El Khouri, E. Dokoupilova, JI. Vargas, M. Stanislavchuk, H. Kellner, E. Baranova, N. Matsunaga, R. Alten,
520    9_
$a OBJECTIVE: To compare the efficacy, serum drug concentrations, immunogenicity, and safety of FKB327 with the adalimumab reference product (RP) in combination with methotrexate in patients with moderate-to-severe, active rheumatoid arthritis (RA). METHODS: Patients were randomized 1:1 in a double-blind study (NCT02260791), received 40 mg of FKB327 or RP by subcutaneous injection every other week for 24 weeks (Period I), then re-randomized 2:1, remaining on the same study drug or switching to the other up to week 54 in an open-label extension (Period II, NCT02405780). Efficacy was evaluated using American College of Rheumatology (ACR20) response rate difference at week 24 with equivalence margins of ± 13% and - 12% to + 15% using 95% and 90% confidence intervals (CIs), respectively. Efficacy, serum drug concentrations, immunogenicity, and safety were compared at week 54. RESULTS: A total of 730 patients were randomized in Period I (n = 367 FKB327, n = 363 RP), and 645 transitioned to Period II (n = 216 FKB327-FKB327, n = 108 FKB327-RP, n = 108 RP-FKB327, n = 213 RP-RP). At week 24, ACR20 response rates were 74.1% with FKB327 versus 75.7% with RP. 95% and 90% CI of the response rate difference were - 7.9 to 4.7% and - 7.3 to 3.6%, respectively, meeting predefined equivalence margins. The ACR20 response rate remained over 70% of patients to week 54 with all treatment sequences. In Period I, mean trough serum drug concentrations were slightly higher for patients receiving FKB327 than those receiving RP. Mean concentrations were stable over time and reflected steady state in Period II. The proportions of patients with samples positive for neutralizing antidrug antibodies (ADAs) were comparable (57.7% with FKB327 vs. 55.5% with RP) at week 24, and no consistent difference in ADA were seen between continuous and switched treatments in Period II. Efficacy was slightly reduced in the small proportion of patients with high ADA titers in all treatment groups. No clinically significant differences were observed in the incidence of commonly reported treatment-emergent adverse events between the treatments across Periods I and II. CONCLUSION: FKB327 was equivalent to RP in clinical efficacy and demonstrated comparable safety and immunogenicity in patients with moderate-to-severe RA. No effect of switching between FKB327 and RP was observed. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02260791, Registered 29 July 2014. ClinicalTrials.gov, NCT02405780, Registered 17 July 2015.
650    _2
$a adalimumab $x aplikace a dávkování $x terapeutické užití $7 D000068879
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antirevmatika $x aplikace a dávkování $x terapeutické užití $7 D018501
650    _2
$a revmatoidní artritida $x farmakoterapie $x patologie $7 D001172
650    _2
$a biosimilární léčivé přípravky $x aplikace a dávkování $x terapeutické užití $7 D059451
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a injekce subkutánní $7 D007279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methotrexát $x aplikace a dávkování $x terapeutické užití $7 D008727
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Glover, Josephine $u Coephycient Pharmaceutical Consultancy, Guildford, UK.
700    1_
$a Greenwald, Maria $u Desert Medical Advances, Palm Desert, CA, USA.
700    1_
$a Porawska, Wieslawa $u Centrum Badań Klinicznych S.C, Poznański Ośrodek Medyczny NOVAMED, Poznań, Poland.
700    1_
$a El Khouri, Elias Chalouhi $u Clínica Internacional, Lima, Peru.
700    1_
$a Dokoupilova, Eva $u MEDICAL PLUS s.r.o., Uherské Hradiště, Czech Republic; Faculty of Pharmacy, Department of Pharmaceutics, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
700    1_
$a Vargas, Juan Ignacio $u Quantum Research, Puerto Varas, Chile.
700    1_
$a Stanislavchuk, Mykola $u National Pirogov Memorial Medical University, Vinnytsia, Ukraine.
700    1_
$a Kellner, Herbert $u Center for Rheumatology and Gastroenterology, Munich, Germany.
700    1_
$a Baranova, Elena $u First Saint-Petersburg State Medical University, St. Petersburg, Russia.
700    1_
$a Matsunaga, Nobuhito $u Fujifilm Kyowa Kirin Biologics, Tokyo, Japan.
700    1_
$a Alten, Rieke $u Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany.
773    0_
$w MED00007534 $t Arthritis research & therapy $x 1478-6362 $g Roč. 21, č. 1 (2019), s. 281
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31831079 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114154815 $b ABA008
999    __
$a ok $b bmc $g 1609045 $s 1119890
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 21 $c 1 $d 281 $e 20191212 $i 1478-6362 $m Arthritis research & therapy $n Arthritis Res Ther $x MED00007534
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace